Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Humans (3)
- Anticoagulants (2)
- Morpholines (2)
- Rivaroxaban (2)
- Thiophenes (2)
-
- Venous Thromboembolism (2)
- Acute Coronary Syndrome (1)
- Adenosine (1)
- Administration (1)
- Animals (1)
- Atrial Fibrillation (1)
- Benzimidazoles (1)
- Clinical Trials as Topic (1)
- Dabigatran (1)
- Dose-Response Relationship (1)
- Drug (1)
- Factor Xa Inhibitors (1)
- Hip Joint (1)
- Nanoparticle (1)
- Neutralizing antibody (1)
- Oral (1)
- Polymer (1)
- Purinergic P2Y Receptor Antagonists (1)
- Pyrazoles (1)
- Pyridines (1)
- Pyridones (1)
- Stroke (1)
- Subunit (1)
- Thiazoles (1)
- Thrombosis (1)
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Hemagglutinin-Based Polyanhydride Nanovaccines Against H5n1 Influenza Elicit Protective Virus Neutralizing Titers And Cell-Mediated Immunity., Kathleen A. Ross, Hyelee Loyd, Wuwei Wu, Lucas Huntimer, Shaheen Ahmed, Anthony R. Sambol, Scott Broderick, Zachary Flickinger, Krishna Rajan, Tatiana K. Bronich, Surya Mallapragada, Michael J. Wannemuehler, Susan Carpenter, Balaji Narasimhan
Hemagglutinin-Based Polyanhydride Nanovaccines Against H5n1 Influenza Elicit Protective Virus Neutralizing Titers And Cell-Mediated Immunity., Kathleen A. Ross, Hyelee Loyd, Wuwei Wu, Lucas Huntimer, Shaheen Ahmed, Anthony R. Sambol, Scott Broderick, Zachary Flickinger, Krishna Rajan, Tatiana K. Bronich, Surya Mallapragada, Michael J. Wannemuehler, Susan Carpenter, Balaji Narasimhan
Journal Articles: Pharmaceutical Sciences
H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to traditional vaccine technologies. In particular, polyanhydride nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-mediated immunity and provide protection upon lethal challenge. In this work, a recombinant H5 hemagglutinin trimer (H5₃) was produced and encapsulated into polyanhydride nanoparticles. The studies performed indicated that the recombinant H5₃ antigen was a robust immunogen. Immunizing mice with H5₃ encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4(+) T …
New Oral Anticoagulants For The Treatment Of Venous Thromboembolism: Understanding Differences And Similarities., Paul P. Dobesh, John Fanikos
New Oral Anticoagulants For The Treatment Of Venous Thromboembolism: Understanding Differences And Similarities., Paul P. Dobesh, John Fanikos
Journal Articles: Pharmacy Practice
Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conventional anticoagulants, including heparin, low-molecular-weight heparins, fondaparinux, and vitamin K antagonists are widely used but have limitations. Newer oral anticoagulant agents, including direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) have been developed to attempt to overcome some of the limitations of conventional anticoagulant therapy. These …
Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, And Safety., Paul P. Dobesh, Julie H. Oestreich
Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, And Safety., Paul P. Dobesh, Julie H. Oestreich
Journal Articles: Pharmacy Practice
Dual antiplatelet therapy, composed of aspirin plus a P2Y12 -receptor antagonist, is the cornerstone of treatment for patients with acute coronary syndrome (ACS). A number of U.S. Food and Drug Administration-approved P2Y12 -receptor antagonists are available for treating patients with ACS, including the thienopyridine compounds clopidogrel and prasugrel. Ticagrelor, the first of a new class of antiplatelet agents, is a noncompetitive, direct-acting P2Y12 -receptor antagonist. Unlike the thienopyridine compounds, ticagrelor does not require metabolism for activity. Also, whereas clopidogrel and prasugrel are irreversible inhibitors of the P2Y12 receptor, ticagrelor binds reversibly to inhibit receptor signaling and subsequent platelet activation. In …
Clinical Use Of Rivaroxaban: Pharmacokinetic And Pharmacodynamic Rationale For Dosing Regimens In Different Indications., Toby Trujillo, Paul P. Dobesh
Clinical Use Of Rivaroxaban: Pharmacokinetic And Pharmacodynamic Rationale For Dosing Regimens In Different Indications., Toby Trujillo, Paul P. Dobesh
Journal Articles: Pharmacy Practice
Target-specific oral anticoagulants have become increasingly available as alternatives to traditional agents for the management of a number of thromboembolic disorders. To date, the direct Factor Xa inhibitor rivaroxaban is the most widely approved of the new agents. The dosing of rivaroxaban varies and adheres to specific schedules in each of the clinical settings in which it has been investigated. These regimens were devised based on the results of phase II dose-finding studies and/or pharmacokinetic modeling, and were demonstrated to be successful in randomized, phase III studies. In most cases, the pharmacodynamic profile of rivaroxaban permits once-daily dosing. A once-daily …
Interaction Of Apobec3a With Dna Assessed By Atomic Force Microscopy., Luda S. Shlyakhtenko, Alexander J. Lushnikov, Ming Li, Reuben S. Harris, Yuri L. Lyubchenko
Interaction Of Apobec3a With Dna Assessed By Atomic Force Microscopy., Luda S. Shlyakhtenko, Alexander J. Lushnikov, Ming Li, Reuben S. Harris, Yuri L. Lyubchenko
Journal Articles: Pharmaceutical Sciences
The APOBEC3 family of DNA cytosine deaminases functions to block the spread of endogenous retroelements and retroviruses including HIV-1. Potency varies among family members depending on the type of parasitic substrate. APOBEC3A (A3A) is unique among the human enzymes in that it is expressed predominantly in myeloid lineage cell types, it is strongly induced by innate immune agonists such as type 1 interferon, and it has the capacity to accommodate both normal and 5-methyl cytosine nucleobases. Here we apply atomic force microscopy (AFM) to characterize the interaction between A3A and single- and double-stranded DNA using a hybrid DNA approach in …